Evidence map›Paper›PMID 40433816›Full record

Trial reportPharmacogenomics

Genomewide association analysis on green tea chemoprevention of colorectal adenoma: the importance of SLCO1A2 variants.

J Stingl, C Scholl, M Steffens, P Koczera, R Muche, F Rohlmann, Th Ettrich, Th Seufferlein

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmacogenomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

J StinglRWTH Aachen, Institute of Clinical Pharmacology, Aachen, Germany.ORCID 0000-0002-1566-8156
C SchollFederal Institute of Drugs and Medical Devices, Research Division, Bonn, Germany.
M SteffensFederal Institute of Drugs and Medical Devices, Research Division, Bonn, Germany.
P KoczeraRWTH Aachen, Institute of Clinical Pharmacology, Aachen, Germany.
R MucheInstitute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
F RohlmannInstitute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
Th EttrichDepartment of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
Th SeufferleinDepartment of Internal Medicine I, Ulm University Hospital, Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGreen tea extract was tested for the secondary prevention of colorectal adenoma in the placebo-controlled MIRACLE trial. Genome-wide screening on adenoma recurrence was performed in

methodsSingle Marker Analysis followed by regression analyses was calculated for all 700.078 markers assuming an additive genetic model and including all covariates from the main MIRACLE trial analysis. The outcome was an adenoma rate at 3-year follow-up colonoscopy comparing participants carrying a genetic variant versus wildtype.

resultsThe gene showing the strongest association with the outcome in both, SMA as well as regression analysis, was the organic anion transporter

conclusionIndividuals with genetic variants in the transporter SLCO1A2 may be protected against colon adenoma irrespective of the green tea intake. In nonvariant carriers of

Indexed as

AdenomaColorectal NeoplasmsOrganic Anion TransportersTeaAgedChemopreventionFemaleGenome-Wide Association StudyHumansMaleMiddle AgedPolymorphism, Single NucleotideOrganic Anion TransportersSLCO1A2 protein, humanTeacatechindrug transportergreen teaGWASnutrikineticsOATP1A2SLCO1A2

Identifiers

PMID40433816
PMCPMC12203844

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.